By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sosei Co., Ltd. 

4F, Kojimachi NK Building
2-14-2 Kojimachi, Chiyoda-ku
Tokyo    102-0083  Japan
Phone: 81-3-5210-3290 Fax: 81-3-5210-3291



Start Up

Company News
Sosei Subsidiary Heptares Announces Positive Outcome Of Phase 1a Study With First-Ever Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Patients With Alzheimer's Disease 6/17/2015 11:16:21 AM
Sosei Snags UK Biotech Firm Heptares for $400 Million 2/23/2015 5:54:15 AM
BioAlliance Pharma Pursues the Development Plan of Its Loramyc® in Japan Through Its Partner Sosei 3/12/2013 12:05:50 PM
BioAlliance Pharma: Progress in the Development of Loramyc(R) in Japan Towards its Registration by the Partner Sosei Co., Ltd. 7/2/2012 12:31:19 PM
BioAlliance Pharma Expands its Loramyc(R) Franchise in Japan With Sosei Co., Ltd. in a Deal Valued up to 18.5M$ 5/11/2011 9:58:06 AM
BioAlliance Expands its Loramyc(R) Franchise in Japan with Sosei Co., Ltd. in a Deal Valued up to $18.5 Million 5/11/2011 6:43:57 AM
Novartis AG, Sosei Co., Ltd. COPD Drug Phase III Trial Meets Primary Endpoint 4/19/2011 7:11:21 AM
Sosei Co., Ltd. Agrees Terms With ASKA Pharmaceutical for Commercialization of SOH-075 (NorLevo(R)) 10/22/2008 9:38:52 AM
Sosei Co., Ltd. Announces Outcome of Strategy Review 5/14/2008 11:35:19 AM
Sosei Co., Ltd. Announces Start of AD 923 Phase III Studies in Europe 2/12/2008 7:22:00 AM